
|Articles|December 1, 2004
Formularies shift quickly as Vioxx drops off the market
The Sept. 30 Voluntary Recall of Vioxx (rofecoxib) by Merck is just another in a long list of headline-making news for the industry. The action was based on the results of a three-year, randomized double-blind trial that indicated that after taking Vioxx for 18 months, patients had twice the risk of heart attack compared with a placebo.
Advertisement
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
The FDA proposes ditching comparative efficacy studies for biosimilars
2
UC Davis develops new drug for bladder cancer patients
3
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
4
Phase 3 trial launches for novel antibody targeting integrin beta-6 in advanced lung cancer
5



















































